Afutuzumab

Afutuzumab
Afutuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD20
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 949142-50-1 N
ATC code None
UNII O43472U9X8 YesY
KEGG D09321 YesY
Chemical data
Formula C6512H10060N1712O2020S44 
Mol. mass 146.1 kDa
 N(what is this?)  (verify)

Afutuzumab is a monoclonal antibody being developed by Hoffmann-La Roche Inc. for the treatment of lymphoma.[1] It acts as an immunomodulator.[2][3] It was renamed to Obinutuzumab in 2009.[4]

References

  1. ^ Robak, T (2009). "GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies". Current opinion in investigational drugs (London, England : 2000) 10 (6): 588–96. PMID 19513948. 
  2. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Afutuzumab, American Medical Association.
  3. ^ International Nonproprietary Names for Pharmaceutical Substances (INN), World Health Organization.
  4. ^ [http://www.who.int/medicines/publications/druginformation/innlists/PLFinal101.pdf International Nonproprietary Names for Pharmaceutical Substances (INN)], World Health Organization.
v · d · eMonoclonal antibodies for tumors
Tumor ("-t(u[m])-")
Human ("-tumu-")

Adecatumumab • Belimumab • Cixutumumab • Conatumumab • Daratumumab • Drozitumab • Figitumumab • Ganitumab • Glembatumumab vedotin • Intetumumab • Iratumumab • Lexatumumab • Lucatumumab • Mapatumumab • Narnatumab • Necitumumab • Ofatumumab • Olaratumab • Panitumumab • Pritumumab • Radretumab • Rilotumumab • Robatumumab • Teprotumumab • Votumumab • Zalutumumab

"-melu-" (melanoma): Flanvotumab
Mouse ("-tumo-")

Altumomab pentetate • Anatumomab mafenatox • Arcitumomab • Bectumomab • Blinatumomab • CC49 • Detumomab • Ibritumomab tiuxetan • Minretumomab • Mitumomab • Moxetumomab pasudotox • Naptumomab estafenatox • Nofetumomab merpentan • Pemtumomab† • Pintumomab • Racotumomab • Satumomab pendetide • Taplitumomab paptox • Tenatumomab • Tositumomab • 3F8

"-govo-" (ovarian tumor): Abagovomab • Igovomab • Oregovomab

"-pro-" (prostate tumor): Capromab pendetide

"-colo-" (colonic tumor): Edrecolomab • Nacolomab tafenatox
Chimeric ("-tuxi-")

Amatuximab • Bavituximab • Brentuximab vedotin • Cetuximab • Ensituximab • Girentuximab • Indatuximab ravtansine • Rituximab • Siltuximab • Ublituximab

"-mexi-" (melanoma): Ecromeximab
Humanized ("-tuzu-")
Afutuzumab • Alemtuzumab • Bevacizumab • Bivatuzumab mertansine • Cantuzumab mertansine • Cantuzumab ravtansine • Citatuzumab bogatox • Clivatuzumab tetraxetan • Dacetuzumab • Dalotuzumab • Elotuzumab† • Etaracizumab • Farletuzumab • Ficlatuzumab • Gemtuzumab ozogamicin • Inotuzumab ozogamicin • Labetuzumab • Lintuzumab • Lorvotuzumab mertansine • Matuzumab§ • Milatuzumab • Nimotuzumab • Onartuzumab • Oportuzumab monatox • Pertuzumab • Sibrotuzumab • Tacatuzumab tetraxetan • Tigatuzumab • Trastuzumab • Tucotuzumab celmoleukin • Veltuzumab
Rat/mouse hybrid ("-tumaxo-")
v · d · eImmunomodulators: Immunosuppressive drugs / Immunosuppressants (L04)
Intracellular
(initiation)

purine synthesis inhibitors: Azathioprine • Mycophenolic acid

pyrimidine synthesis inhibitors: Leflunomide • Teriflunomide

antifolate: Methotrexate
Macrolides/
other IL-2 inhibitors
TNF-α inhibitor
Intracellular
(reception)
Sirolimus • Deforolimus • Everolimus • Temsirolimus • Zotarolimus • Biolimus A9
Extracellular
Serum target
(noncellular)
Cellular target
Unsorted
-cept (Fusion)

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug(L3/4)


Stub icon This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.